Abstract
Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is quickly becoming a routine and effective means by which to treat degenerated bioprosthetic valves. A known complication of ViV-TAVR is patient-prosthesis mismatch, which significantly impacts survival. Bioprosthetic valve fracture is a method by which some operators reduce the risk of patient-prosthesis mismatch and reduce ViV-TAVR gradients. We sought to determine the utilization of ViV-TAVR fracturing at our institution and its effectiveness in reducing residual transvalvular gradients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Society for Cardiovascular Angiography & Interventions
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
